GSK
GSK plc
Set alert
- YTD
- +0.96%
- 1 year
- +5.48%
- Open
- 49.84
- Prev close
- 48.68
- Mkt cap
- 99.19B
- Vol
- 4.77M
- Avg vol
- 4.07M
- EPS
- 2.87
- P/E
- 17.25
- Div yield
- 3.73%
More statistics
- Low
- 49.25
- High
- 50.28
- Forward P/E
- 9.99
- Beta
- 0.28
- Short ratio
- 2.86
- Inst. own
- 17.46%
- Dividend
- 1.82
- Ex-div date
- Aug 13, 2026
- Earnings
- Feb 3, 2027
- 50-d avg
- 49.48
- 200-d avg
- 52.35
- 1y target
- 60.40
Key statistics
- Market cap
- 99.12B
- Enterprise value
- 118.03B
- Trailing P/E
- 17.24
- Forward P/E
- 9.99
- PEG ratio
- 5.89
- Price / sales
- 2.96
- Price / book
- 3.95
- EPS (TTM)
- 2.87
- Beta
- 0.28
- Dividend yield
- 3.73%
- Payout ratio
- 63.33%
- Profit margin
- 12.97%
- Revenue (TTM)
- 33.54B
- Revenue growth
- 4.00%
- Free cash flow
- 5.33B
- Total cash
- 2.96B
- Total debt
- 23.80B
- Return on equity
- 28.27%
- Shares outstanding
- 2.00B
- Short % of float
- 0.73%
- 50-day average
- 49.48
- 200-day average
- 52.35
Analyst view
Consensus: buy
- Target (low)
- 49.00
- Target (mean)
- 60.40
- Target (high)
- 70.00
- Strong buy1
- Buy3
- Hold4
- Sell1
- Strong sell0
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 0.74766.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 0.77 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 1.33 | 1.47 | +0.14 | +10.53% |
| Jul 28, 2026 | Jun 30, 2026 | 1.27 | 1.36 | +0.09 | +7.09% |
| Apr 29, 2026 | Mar 31, 2026 | 1.16 | 1.24 | +0.08 | +6.90% |
| Feb 4, 2026 | Dec 31, 2025 | 0.64 | 0.68 | +0.04 | +6.25% |
| Oct 29, 2025 | Sep 30, 2025 | 1.26 | 1.48 | +0.22 | +17.46% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Jefferies | down | Buy | Hold |
| Jan 6, 2026 | Barclays | down | Equal-Weight | Underweight |
| Nov 12, 2024 | Jefferies | down | Buy | Hold |
| Oct 31, 2024 | Guggenheim | down | Buy | Neutral |
| Jul 8, 2024 | UBS | down | Buy | Neutral |
| Jul 2, 2024 | Jefferies | main | Buy | Buy |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United Kingdom
- Website
- gsk.com
News
- GSK: The Gas Pedal Is Still Down, But Bumps Ahead
- Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9
- GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
- GSK plc (GSK) Q3 2026 Earnings Call Transcript
- What GSK (GSK) Said on Its Q3 Earnings Call
- GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
- GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
- GSK’s Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
- GSK: Why I'm Still Bullish After Strong Q3 Results
- UPDATE: GSK Q3 Adj. EPS $1.47 Beats $1.40 Estimate, Sales $11.948B Beat $11.800B Estimate
Your note
Sign in to keep a note on GSK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Anderson (Elizabeth McKee) | — | Bought | Oct 8, 2026 | 4,938 |
| Bancroft (Charles A) | — | Bought | Oct 8, 2026 | 45,579 |
| Barron (Hal V) | — | Bought | Oct 8, 2026 | 604,639 |
| Beal (Anne M.D.) | — | Bought | Oct 8, 2026 | 5,663 |
| Conrad (D) | — | Bought | Apr 26, 2026 | 7,571 |
| Dietz (Hal) | — | Bought | Oct 8, 2026 | 5,589 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 3.21% | 64,961,641 | 3.21B | Jun 29, 2026 |
| Dodge & Cox Inc. | 2.38% | 48,197,514 | 2.38B | Jun 29, 2026 |
| Fisher Asset Management, LLC | 1.77% | 35,722,792 | 1.77B | Jun 29, 2026 |
| Primecap Management Company | 1.24% | 25,182,068 | 1.25B | Jun 29, 2026 |
| Wellington Management Group, LLP | 0.56% | 11,396,249 | 563.83M | Jun 29, 2026 |
| JTC Employer Solutions Trustee Ltd. | 0.42% | 8,592,987 | 425.14M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 1.76% | 35,573,787 | 1.76B | Jun 29, 2026 |
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 0.90% | 18,172,650 | 899.09M | Jun 29, 2026 |
| VANGUARD WELLINGTON FUND | 0.47% | 9,498,942 | 469.96M | Aug 30, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 0.40% | 8,018,227 | 396.70M | Aug 30, 2026 |
| Fidelity Hastings Street Trust-Fidelity Series Large Cap Stock Fund | 0.23% | 4,579,628 | 226.58M | Aug 30, 2026 |
| Fidelity Devonshire Trust-Fidelity Series Value Discovery Fund | 0.20% | 3,952,000 | 195.53M | Aug 30, 2026 |